SCHEMBL212020

SCHEMBL212020

C[C@H](O)c1cccc(S(C)(=O)=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
GAA P10253 1/20 0.49
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NLRP3 Q96P20 1/20 0.46
ADRA1D P25100 1/20 0.45
AKR1C3 P42330 2/20 0.42
AKR1C2 P52895 2/20 0.42
ENPP2 Q13822 1/20 0.42
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
KCNQ4 P56696 1/20 0.41
KCNQ5 Q9NR82 1/20 0.41
UGT2B7 P16662 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214314 1.00 ALDH1A1 (0.49) ALDH1A1GAACYP3A4CYP2D6SLC6A2
SCHEMBL213363 1.00 ALDH1A1 (0.49) ALDH1A1GAACYP3A4CYP2D6SLC6A2
SCHEMBL30661278 1.00 ALDH1A1 (0.49) ALDH1A1GAACYP3A4CYP2D6SLC6A2
SCHEMBL84445 0.84 ALDH1A1 (0.47) ALDH1A1GAACYP3A4CYP2D6SLC6A2
SCHEMBL7137010 0.83 CA2 (0.57) MEN1KMT2ANLRP3
SCHEMBL22181477 0.82 ALDH1A1 (0.46) ALDH1A1GAACYP3A4CYP2D6SLC6A2
SCHEMBL1738688 0.81 ALDH1A1 (0.45) ALDH1A1GAACYP3A4CYP2D6SLC6A2
SCHEMBL212786 0.81 ALDH1A1 (0.45) ALDH1A1GAACYP3A4CYP2D6SLC6A2
SCHEMBL213023 0.81 ALDH1A1 (0.45) ALDH1A1GAACYP3A4CYP2D6SLC6A2
SCHEMBL17061124 0.81 ALDH1A1 (0.45) ALDH1A1GAACYP3A4CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018097944-A1 TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2018-05-31 WO disclosed
US-9440992-B2 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors Acturum Life Science AB (SE) 2016-09-13 US disclosed
US-8088780-B2 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors ASTRAZENECA AB (SE) 2012-01-03 US disclosed
US-7947693-B2 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma ASTRAZENECA AB (SE) 2011-05-24 US disclosed
US-20110092519-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS ASTRAZENECA AB (SE) 2011-04-21 US disclosed
CN-101193897-B Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives ASTRAZENECA AB 2010-12-01 CN disclosed
CN-101193898-B Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives ASTRAZENECA AB 2010-12-01 CN disclosed
EP-1869056-B1 NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2010-11-10 EP disclosed
US-20090124637-A1 Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 ASTRAZENECA AB (SE) 2009-05-14 US disclosed
US-20080214578-A1 Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 ACTURUM REAL ESTATE AB (SE) 2008-09-04 US disclosed
CN-101193898-A Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives ASTRAZENECA AB (SE) 2008-06-04 CN disclosed
CN-101193897-A Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives ASTRAZENECA AB (SE) 2008-06-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092519-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS CX3CR1, CCR2, CXCR3 ALDH1A1 1415/4885GAA 4565/4885CYP3A4 2174/4885
US-20080214578-A1 Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 CX3CR1, CCR2, CXCR3 ALDH1A1 1833/4885GAA 4276/4885CYP3A4 1442/4885
US-20090124637-A1 Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 CX3CR1, CCR2, CCR5 ALDH1A1 897/4885GAA 4201/4885CYP3A4 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.